What steps can be taken to counter the increasing failure of miltefosine to treat visceral leishmaniasis?

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 2, 2013, Pages 117-119

  Sundar, Shyam ^a   Singh, Anup ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MILTEFOSINE;

AWARENESS; CLINICAL ASSESSMENT; CONTINUING EDUCATION; DIRECTLY OBSERVED THERAPY; DRUG COMBINATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEALTH CARE AVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEDICAL EDUCATION; MIXED INFECTION; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; REVIEW; SIDE EFFECT; TERATOGENESIS; VISCERAL LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; CLINICAL PROTOCOLS; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HUMANS; INDIA; LEISHMANIASIS, VISCERAL; MEDICATION ADHERENCE; PHOSPHORYLCHOLINE;

EID: 84873937558     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.170     Document Type: Review

References (18)

1. Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352(9143), 1821-1823 (1998).
2. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347(22), 1739-1746 (2002).
3. Sundar S, Mondal D, Rijal S et al. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal - the challenges for diagnosis and treatment. Trop. Med. Int. Health 13(1), 2-5 (2008).
4. Bhattacharya SK, Sinha PK, Sundar S et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 196(4), 591-598 (2007).
5. Sundar S, Singh A, Rai M et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 55(4), 543-550 (2012).
6. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31(4), 1104-1107 (2000).
7. WHO. Control of the leishmaniases - report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. In: WHO Technical Report Series, No. 949. WHO, Geneva, Switzerland (2010).
8. Sundar S, Rai M, Chakravarty J et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis. 47(8), 1000-1006 (2008).
9. Sundar S, Sinha PK, Rai M et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, noninferiority, randomised controlled trial. Lancet 377(9764), 477-486 (2011).
10. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50(1), 73-79 (2006).
11. Bhandari V, Kulshrestha A, Deep DK et al. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl. Trop. Dis. 6(5), e1657 (2012).
12. Coelho AC, Leprohon P, Ouellette M. Generation of Leishmania hybrids by whole genomic DNA transformation. PLoS Negl. Trop. Dis. 6(9), e1817 (2012).
13. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem. 278(50), 49965-49971 (2003).
14. Seifert K, Perez-Victoria FJ, Stettler M et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int. J. Antimicrob. Agents 30(3), 229-235 (2007).
15. Perez-Victoria FJ, Sanchez-Canete MP, Seifert K et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist. Updat. 9(1-2), 26-39 (2006).
16. Sanchez-Canete MP, Carvalho L, Perez-Victoria FJ, Gamarro F, Castanys S. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob. Agents Chemother. 53(4), 1305-1313 (2009).
17. Fernandez O, Diaz-Toro Y, Valderrama L et al. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. J. Clin. Microbiol. 50(7), 2207-2211 (2012).
18. Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev. 21(2), 334-59 (2008).